We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · November 24, 2021

Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
J Thorac Oncol 2021 Nov 02;[EPub Ahead of Print], YL Wu, T John, C Grohe, M Majem, JW Goldman, SW Kim, T Kato, K Laktionov, HV Vu, Z Wang, S Lu, KY Lee, C Akewanlop, CJ Yu, F de Marinis, L Bonanno, M Domine, FA Shepherd, L Zeng, A Atasoy, RS Herbst, M Tsuboi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading